Year: 2021

– New findings presented at ASH support development strategy for KO-539 in KMT2A-rearranged and NPM1-mutant AML – SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the presentation of new preclinical data for KO-539, the Company’s oral, potent and selective menin inhibitor, and its potential for synergistic activity in combination with venetoclax, a current standard of care in the treatment of patients with acute myeloid leukemia (AML). The new findings, generated through a research collaboration with Dr. Kapil Bhalla at the MD Anderson Cancer Center, are being presented during a poster session today at the American Society of Hematology (ASH) Annual meeting...

TULSA, Okla., Dec. 13, 2021 (GLOBE NEWSWIRE) — Blueknight Energy Partners, L.P. (“Blueknight” or the “Partnership”) (Nasdaq: BKEP and BKEPP), announced today that it has entered into a definitive agreement to acquire an asphalt terminal and 200-acre industrial park in Colorado and, in a separate arrangement, entered into a definitive agreement to organically expand the storage, logistics, and product capabilities at an existing asphalt terminal owned by Blueknight. The projects were approved by Blueknight’s Board of Directors. The combined capital requirements for the two growth projects are expected to range between $14 and $16 million initially, with potential future expansion opportunities ranging between $5 and $10 million in additional growth capital. The projects will be funded with borrowings available under Blueknight’s...

Xos Stepvan for Merchants Fleet100% Battery Electric Xos Stepvan with Merchants Fleet BrandingMerchants Orders Fully Electric Step Vans from Xos, Inc.New commitment to purchase Xos EVs moves Merchants Fleet closer to 50% electrification of mobility fleet portfolio by 2025, 50% electrification of its managed fleet portfolio by 2030. Offers electrification option for Merchants’ last mile and delivery clients Merchants has committed over $2B to fleet electrification, with intent to buy more than 40,000 electric vehicles The new Xos Electric step vans will be deployed in 2022LOS ANGELES, Dec. 13, 2021 (GLOBE NEWSWIRE) — Xos, Inc (NASDAQ: XOS), a leading manufacturer of fully electric Class 5 to Class 8 commercial vehicles, today announced a strategic partnership with Merchants Fleet, the nation’s fastest growing...

CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies, will provide a clinical update on CLN-081 during a webinar on Thursday, December 16, 2021, at 8:00 a.m. ET. During the webinar, Cullinan’s team will review updated safety and efficacy data from an ongoing Phase 1/2a trial evaluating CLN-081 in non-small cell lung cancer (NSCLC) patients harboring Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after prior therapy. CLN-081 Clinical Update Webinar Information Participants can register for the webinar through the events section on Cullinan’s investor website. An archived recording of the live audio webcast will be available on Cullinan’s...

BOCA RATON, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO First Wave BioPharma, has issued a Letter to Shareholders in connection with the Company’s 2021 Annual Meeting of Stockholders, to be held on December 17, 2021 at 9:00 a.m. EST. The letter provides an update on recent events and an outlook for the Company’s clinical programs in 2022. The full text of the letter follows.  A MESSAGE FROM OUR CHAIRMAN AND CHIEF EXECUTIVE OFFICER Dear Fellow Shareholders: First Wave BioPharma is a company transformed, and I write to you today as excited...

3-part randomized, double-blind, placebo-controlled Phase 1 study will evaluate TRV045 safety, tolerability, and PK in healthy volunteers Enrollment expected to start in early Q1 2022 CHESTERBROOK, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it is advancing TRV045 into clinical development, following receipt of a notification from the U.S. Food and Drug Administration (FDA) that the study may proceed. TRV045 is the Company’s novel S1P1 receptor modulator being developed as a potential treatment for diabetic neuropathic pain (DNP). In addition, through a collaboration with the National Institutes of Health, the Company is also exploring TRV045...

– Data Underscore Potential of Mitapivat to Provide Clinically Meaningful Outcomes for Patients – – Safety Profile Consistent with Previously Reported Clinical Data – – Agios Announces Initiation of Phase 2/3 RISE UP Study of Mitapivat in Adults with Sickle Cell Disease – – Agios to Host Investor Webcast on Dec. 14, 2021, at 7:30 a.m. ET – CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced new data from investigator-led studies of mitapivat, a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase (PK) enzymes, in adults with sickle cell disease. The data, reported by the National Institutes of Health (NIH) and University...

TNX-1700 is Under Development as Monotherapy and in Combination with Anti-PD1 Checkpoint Inhibitor Therapy in Animal Models of Two Challenging Cancers In Mouse Models, rTFF2 Detoxifies the Tumor Microenvironment, Allows Activation of Cancer-Killing CD8+T Cells and Limits Immune Evasion by Cancer Cells Study to be Led by Noted Cancer Researcher and Columbia Professor Timothy C. Wang, M.D. CHATHAM, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has entered into a research collaboration with Columbia University (Columbia) focused on advancing recombinant trefoil factor family 2 (rTFF2)-based therapeutic candidates (TNX-1700) in the treatment of gastric and colorectal cancers. Tonix licensed worldwide...

TORONTO, Dec. 13, 2021 (GLOBE NEWSWIRE) — Osisko Mining Inc. (TSX:OSK) (the “Corporation“) is pleased to announce that it has received conditional approval of the Toronto Stock Exchange to extend the expiry date of the common share purchase warrants of the Corporation (the “Warrants“) originally issued pursuant to a private placement of units of the Corporation, which closed on June 23, 2020 (the “Offering“). The Warrants are exercisable for common shares of the Company (“Common Shares“) at a price of $5.25 per Common Share and are set to expire on December 23, 2021. The Company has extended the expiry date of such Warrants by an additional six months to June 23, 2022, with such extension being effective on December 29, 2021 (the “Effective Date“). All other terms of the...

Partnership will provide credit education tool to HomeFree-USA customers, primarily first time homebuyers of color CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) — As racial disparities in homeownership reach their highest levels in nearly 50 years, today TransUnion (NYSE: TRU) announced a partnership with HomeFree-USA, a leading nonprofit homeownership development and financial empowerment organization. TransUnion is supporting HomeFree-USA in guiding more Black Americans to achieve and sustain homeownership by providing the CreditView Dashboard®, a credit education tool, free of charge as part of HomeFree’s credit counseling and education program. “At TransUnion, we’re committed to fostering a more inclusive financial system where everyone can achieve their goals,” said Chris Cartwright, president and CEO, TransUnion. “Credit is a fundamental...